Moderna Inc.
No price chart data available for 1D timeframe.
Rating
Why Price Moved
Shares are trading higher following optimistic com...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and deve...
Latest News
19 hours ago · youtube.com
Moderna, Merck eye FDA approval for promising cancer vaccineModerna co-founder and board chairman Noubar Afeyan discusses the biotech company's melanoma vaccine trial results and efforts to secure FDA approval on 'The Claman Countdown.' #fox #foxbusiness #media #breakingnews #us #usa #new #news #breaking #theclamancountdown #moderna #merck #nubarafeyan #afeyan #cancer #cancervaccine #melanoma #cancerresearch #cancertreatment #vaccines #biotech #biotechnology #healthcare #healthnews #medicalresearch #clinicaltrials #fda #fdaapproval #immunotherapy #pharmaceuticals #medicine #medicalinnovation #cancerprevention #healthtechnology #drugdevelopment #lifesciences
2 days ago · zacks.com
Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to DeclineModerna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 days ago · zacks.com
Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to KnowModerna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
4 days ago · fool.com
Will Moderna Soar on Nov. 6?Investors are excited about Moderna's personalized cancer vaccine candidate, which recently delivered positive clinical trial data. The stock surged after data was released in August but has given up some gains in recent days.
4 days ago · wsj.com
Moderna's CEO told The Wall Street Journal that his cancer vaccine's data will get better with time, and that no one can easily copy the company's workStéphane Bancel defended his melanoma data and argued that rivals can't easily copy the technology.
4 days ago · 247wallst.com
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge HigherShrugging off a valuation downgrade, Moderna (NASDAQ:MRNA | MRNA Price Prediction) is climbing as investors weigh strong cancer vaccine data against a share price that already reflects big expectations. Moderna stock stands at $217, up 4% this morning.
4 days ago · fool.com
Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp VolatilityAxsome Therapeutics (AXSM -1.29%) primarily discovers, develops, and exclusively commercializes innovative medical treatments targeting numerous central nervous system disorders domestically.
5 days ago · marketbeat.com
Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid?Merck & Co. NYSE: MRK and Moderna NASDAQ: MRNA just cleared a bar no cancer vaccine had cleared before. Their personalized melanoma vaccine succeeded in a Phase 3 trial.
5 days ago · benzinga.com
William Blair Takes a Shot at Moderna Stock: Downgrade to Market Perform After a 545% RunModerna Inc. (NASDAQ:MRNA) shares are trading lower Tuesday after William Blair downgraded the stock to Market Perform from Outperform on Monday, citing valuation concerns.
5 days ago · barrons.com
Moderna Has Its Doubters. CEO Bancel Plans to Answer With a Cancer Shot.Moderna CEO Stéphane Bancel says the biotech's competitive edge stems from its mRNA platform, likening it to software in Big Tech.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove MRNA